Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients

Transplantation Proceedings

Volumn 36, Issue 4, 2004, Pages 1082-1083

  Stratta, R J ^a,b   Alloway, R R ^a   Lo, A ^a   Hodge, E E ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; AFRICAN AMERICAN; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DONOR; EXPOSURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; NONHUMAN; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RISK FACTOR; SERODIAGNOSIS; SEROLOGY; TREATMENT OUTCOME;

CONTINENTAL POPULATION GROUPS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 2942642550     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.04.066     Document Type: Conference Paper

References (3)

1. Fisherman J.A., Rubin R.H. Infection in organ transplant recipients. N Engl J Med. 338:1998;1741
2. Lo A., Stratta R.J., Egidi M.F., et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transplant Infect Dis. 3:2001;8
3. Stratta R.J., Alloway A.A., Lo A., et al. PIVOT investigators. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients primary endpoint analysis of a multicenter, randomized study. Transplantation. 75:2003;1260